- Associated Press - Thursday, November 18, 2010

Pfizer Inc. says it is halting a key study of its experimental blood thinner, apixaban, because of dangerous bleeding among patients with a history of heart disease.

The drug, co-developed with Bristol-Myers Squibb Corp., has been touted as a potential blockbuster drug that could prevent heart attack and stroke without the bleeding side effects associated with older medications.

But Pfizer says it is halting a 10,000-patient study of the drug because of “a clinically important increase in bleeding among patients.”

The New York-based company is studying the drug for other uses to prevent blood clots and stroke in patients with irregular heartbeats.

Apixaban works by blocking a clotting protein called factor Xa. That is in contrast to drugs like Plavix, which work by preventing platelets from sticking together.

LOAD COMMENTS ()

 

Click to Read More

Click to Hide